Rapamycin neurovascular Balloon Catheter
DeviceDrug-coated balloon for the symptomatic cerebral atherosclerotic stenosis
NCT Number: NCT06683118
The purpose of the trail is to determine whether DCB is superior to conventional balloon in treating cerebral atherosclerotic stenosis
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Tiantan Hospital Affiliated of Peking University, Beijing, Beijing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Incsion Criteria:
Exclusion criteria
Drug-coated balloon for the symptomatic cerebral atherosclerotic stenosis
Conventional Balloon for the symptomatic cerebral atherosclerotic stenosis
Time frame: 180±30days
The primary endpoint was the restenosis rate at 6 month postoperatively. Restenosis was defined as ≥50% measured stenosis of the target lesion by imaging according to WASID method.
Time frame: Intraoperation
defined as smooth delivery of the device to the target lesion and successful dilatation, unloading, and retraction
Time frame: 30±7days
Time frame: 30±7days
Time frame: 180±30days
Time frame: 180±30days
Time frame: 360±60days
Time frame: 360±60days
MicroPort NeuroTech Co., Ltd.
Industry
A PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SUPERIORITY, RANDOMIZED, CONTROLLED REGISTRATION TRIAL OF THE RAPAMYCIN NEUROVASCULAR BALLOON CATHETER FOR THE TREATMENT OF SYMPTOMATIC CEREBRAL ATHEROSCLEROTIC STENOSIS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.